Form 4: PTC Therapeutics EVP Granted Equity Awards

PTC Therapeutics' EVP & Chief Medical Officer, Lee Scott Golden, was granted 18,750 restricted stock units and options for 46,875 shares of common stock.

Summary

• Lee Scott Golden, Executive Vice President and Chief Medical Officer of PTC Therapeutics, Inc. (PTCT), was granted equity awards on January 2, 2026.
• The grants include 18,750 shares of common stock in the form of Restricted Stock Units (RSUs) at a price of $0.
• These RSUs will vest in four equal annual installments, commencing on January 2, 2027.
• Additionally, 46,875 stock options were granted with an exercise price of $76.74.
• The stock options vest over four years, with 25% vesting on January 2, 2027, and an additional 6.25% vesting at the end of each successive three-month period thereafter, beginning on April 2, 2027.
• The stock options have an expiration date of January 1, 2036.
• Following these transactions, Lee Scott Golden beneficially owns 95,276 shares of common stock directly, which includes 272 shares acquired under the employee stock purchase plan for the period ended June 30, 2025, and 257 shares for the period ended December 31, 2025.
• Golden also directly beneficially owns 46,875 derivative securities in the form of stock options.

Sentiment

Score: 7

Explanation: The filing details routine executive compensation through equity grants, which is a positive for aligning management's interests with shareholders. It does not contain information that would significantly alter the company's fundamental outlook, but reinforces executive commitment.

Positives

• The grant of equity awards to a key executive, Lee Scott Golden, aligns management's long-term interests with those of shareholders, incentivizing performance and retention.
• The vesting schedules for both RSUs and stock options are structured over several years, promoting sustained commitment to the company's success.

Future Outlook

The equity grants provide a forward-looking incentive for the executive, with vesting schedules extending over the next four years, aligning future performance with shareholder value creation.

Industry Context

Executive equity grants, such as Restricted Stock Units and stock options, are a standard component of compensation packages in the biotechnology and pharmaceutical industries, designed to attract, retain, and motivate key talent by linking their financial success to the company's long-term performance.

Related Party Transactions

• Grant of 18,750 Restricted Stock Units to Lee Scott Golden, EVP & Chief Medical Officer.
• Grant of 46,875 Stock Options to Lee Scott Golden, EVP & Chief Medical Officer.

Stakeholder Impact

• Shareholders: The equity grants align the interests of a key executive with shareholders, potentially leading to improved long-term performance and value creation.
• Employees: Standard executive compensation practices can positively influence overall employee morale and retention by demonstrating a commitment to rewarding leadership.

Next Steps

• Vesting of 25% of the Restricted Stock Units on January 2, 2027.
• Vesting of 25% of the Stock Options on January 2, 2027.
• Subsequent quarterly vesting of 6.25% of the original stock options beginning April 2, 2027.

Key Dates

Recommendation

The filing details standard executive compensation through equity grants, which aligns management's interests with shareholders. This is a routine disclosure and does not provide new information warranting a change in investment thesis, thus a 'hold' recommendation is appropriate. It reinforces executive commitment but does not present new fundamental data to justify a 'buy' or 'sell' action.

Keywords

PTC Therapeutics, PTCT, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Executive Compensation, Lee Scott Golden, Chief Medical Officer